KYDVEVO Trademark

Trademark Overview


On Friday, June 2, 2023, a trademark application was filed for KYDVEVO with the United States Patent and Trademark Office. The USPTO has given the KYDVEVO trademark a serial number of 98025511. The federal status of this trademark filing is REQUEST FOR EXTENSION OF TIME TO FILE OPPOSITION as of Tuesday, September 17, 2024. This trademark is owned by ProKidney. The KYDVEVO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and biologic preparations for treating and managing chronic kidney disease; Pharmaceutical and biologic preparations for preventing, treating, and delaying diseases, disorders, and conditions affecting the kidneys; Therapeutic agents for promoting kidney function and structure; Biological compounds for medical use, namely, formulated selected renal cells delivered into patient's damaged kidney for repairing damaged tissue and restoring kidney function; Autologous homologous cell mixture for renal therapeutic purposes; Medicaments for personalized cell therapy used in renal diseases, disorders, and conditions
kydvevo

General Information


Serial Number98025511
Word MarkKYDVEVO
Filing DateFriday, June 2, 2023
Status802 - REQUEST FOR EXTENSION OF TIME TO FILE OPPOSITION
Status DateTuesday, September 17, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 27, 2024

Trademark Statements


Goods and ServicesPharmaceutical and biologic preparations for treating and managing chronic kidney disease; Pharmaceutical and biologic preparations for preventing, treating, and delaying diseases, disorders, and conditions affecting the kidneys; Therapeutic agents for promoting kidney function and structure; Biological compounds for medical use, namely, formulated selected renal cells delivered into patient's damaged kidney for repairing damaged tissue and restoring kidney function; Autologous homologous cell mixture for renal therapeutic purposes; Medicaments for personalized cell therapy used in renal diseases, disorders, and conditions

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, July 7, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameProKidney
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGrand Cayman KY1-9006
KY

Party NameProKidney
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGrand Cayman KY1-9006
KY

Trademark Events


Event DateEvent Description
Tuesday, June 6, 2023NEW APPLICATION ENTERED
Saturday, February 24, 2024ASSIGNED TO EXAMINER
Friday, March 1, 2024NON-FINAL ACTION WRITTEN
Friday, March 1, 2024NON-FINAL ACTION E-MAILED
Friday, March 1, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 16, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 16, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, May 21, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, May 21, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Friday, July 7, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 22, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 22, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 22, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 22, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 7, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 27, 2024PUBLISHED FOR OPPOSITION
Tuesday, August 27, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 17, 2024EXTENSION OF TIME TO OPPOSE RECEIVED